Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
-
Patent number: 12226381Abstract: The present disclosure provides a pharmaceutical composition of fused tricyclic gamma-amino acid derivatives and the use thereof. The pharmaceutical composition includes: (i) a compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, as an active material, in an amount of 1% to 45% by weight; (ii) optionally one or more fillers in an amount of 50% to 95% by weight; (iii) optionally one or more lubricating agents in an amount of 0.1% to 5.Type: GrantFiled: July 12, 2019Date of Patent: February 18, 2025Assignee: SICHUAN HAISCO PHARMACEUTICAL CO., LTD.Inventors: Xuanmiao Zhang, Feng Peng, Hua Mao, Juanjuan Deng, Pangke Yan
-
Patent number: 12220466Abstract: A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.Type: GrantFiled: May 24, 2024Date of Patent: February 11, 2025Inventor: Larry P. Bleier
-
Patent number: 12214106Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.Type: GrantFiled: March 7, 2023Date of Patent: February 4, 2025Assignee: Sofregen Medical, Inc.Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
-
Patent number: 12175354Abstract: An apparatus for training a tunable data structure to predict internal ribosome entry site (IRES) activity includes at least a processor and a memory containing instructions configuring the at least a processor to assemble a training set including a plurality of nucleotide sequence data examples IRES sequences and a plurality of correlated observed IRES activity, partition the training set into at least a first section and a second section, train, using the first section at least an activity data structure to generate probable IRES activity using nucleotide sequence data, and iteratively retrain the at least an activity data structure using the second section, wherein each iteration of the iterative retraining includes generating a predicted IRES activity value using the at least an activity neural network and a nucleotide sequence data example, evaluating an error function, and tuning the activity data structure.Type: GrantFiled: March 11, 2024Date of Patent: December 24, 2024Assignee: Orna Therapeutics, Inc.Inventors: Ramin Dehghanpoor, Varun Shivashankar
-
Patent number: 12070507Abstract: One aspect of the invention provides a method for reducing inflammation in a patient including locally administering a composition comprising a complex comprising octadecylamine surface-functionalized nanodiamonds with dexamethasone bound to octadecylamine. Another aspect of the invention provides a method for reducing inflammation in a patient comprising locally administering a composition including octadecylamine surface-functionalized nanodiamonds, wherein no therapeutic agent is bound to the nanodiamonds.Type: GrantFiled: March 3, 2022Date of Patent: August 27, 2024Assignee: Drexel UniversityInventors: Kara Lorraine Spiller, Amanda Elizabeth Pentecost, Yury Gogotsi
-
Patent number: 12059500Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.Type: GrantFiled: May 10, 2023Date of Patent: August 13, 2024Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.Inventors: Wassana Yantasee, Moataz Reda, Worapol Ngamcherdtrakul
-
Patent number: 12011455Abstract: A method for reducing or substantially preventing soft tissue calcification is provided. The method includes administering at least one of a downregulator of at least one plasmin inhibitors and plasmin(ogen) to a subject in need thereof, wherein the at least one plasmin inhibitor includes alpha2-antiplasmin. Further disclosed is a method comprises administering the compound subsequent to muscle injury, and the method further comprising administering an antifibrinolytic.Type: GrantFiled: March 17, 2017Date of Patent: June 18, 2024Assignee: Vanderbilt UniversityInventors: Jonathan Schoenecker, Masato Yuasa
-
Patent number: 11963944Abstract: A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing a powder composition having an amount of one or more cannabinoids and a water-insoluble composition including cellulose and/or fibers in the form of particles in an amount of 30 to 80% by weight of the powder composition. The powder composition further includes a water-soluble composition comprising one or more sugar alcohols and the pouch includes a water-permeable membrane. A pouch designed for administration of an active ingredient in the oral cavity is also disclosed.Type: GrantFiled: November 16, 2022Date of Patent: April 23, 2024Assignee: NordicCan A/SInventor: Heidi Ziegler Bruun
-
Patent number: 11938172Abstract: The present invention discloses the use of plasminogen to regulate GLP-1/GLP-1R and treat a GLP-1/GLP-1R-related condition.Type: GrantFiled: June 19, 2018Date of Patent: March 26, 2024Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11903966Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: GrantFiled: November 5, 2018Date of Patent: February 20, 2024Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, INTIMA BIOSCIENCE, INC., The U.S.A., as represented by the Secretary, Department f Health and Human ServicesInventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Patent number: 11850323Abstract: A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures.Type: GrantFiled: December 7, 2020Date of Patent: December 26, 2023Assignee: 206 ORTHO, INC.Inventors: Jeffrey A. D'Agostino, Andrew J. Carter, Craig M. Jones, Arthur C. Watterson
-
Patent number: 11821892Abstract: The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.Type: GrantFiled: April 17, 2020Date of Patent: November 21, 2023Assignee: Purdue Research FoundationInventors: Joseph Irudayaraj, Pushpak Bhandari
-
Patent number: 11786471Abstract: A complex disintegrant composition for oral solid preparation, comprising a disintegrant and a disintegrating aid, the disintegrant being a hygroscopic expansion type disintegrant, the disintegrating aid being a soluble small molecule substance or a gas-producing type salt. An oral solid preparation, comprising an active ingredient, said complex disintegrant composition, an excipient and a lubricant.Type: GrantFiled: June 27, 2017Date of Patent: October 17, 2023Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD.Inventors: Yaowen Wan, Yongkai Chen, Xian Zeng, Chaodong Wang, Wei Feng
-
Patent number: 11655469Abstract: Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5?-end and/or 3?-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.Type: GrantFiled: March 7, 2017Date of Patent: May 23, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, miRenlo, Inc.Inventors: Anthony D. Saleh, Carter Van Waes, Zhong Chen, Hui Cheng
-
Patent number: 11617815Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.Type: GrantFiled: October 31, 2017Date of Patent: April 4, 2023Assignee: Sofregen Medical, Inc.Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
-
Patent number: 11612568Abstract: The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.Type: GrantFiled: April 17, 2020Date of Patent: March 28, 2023Assignee: DFE PHARMA GMBH & CO. KGInventors: Korinde Van Den Heuvel, Bas Van Laarhoven, Eva Maria Janssen, Mara Maria Wilhelmina Van Haandel
-
Patent number: 11607407Abstract: The present invention is directed to therapeutic pharmaceutical compositions of 1-Methyl-2?, 6?-pipecoloxylidide or it pharmaceutically acceptable salts for application to the skin and the use thereof.Type: GrantFiled: April 13, 2011Date of Patent: March 21, 2023Assignee: Relmada Therapeutics, Inc.Inventor: Najib Babul
-
Patent number: 11590253Abstract: A composite material is formed by combining an expandable polymer having a charge with another polymer having an opposite charge to produce. In particular, the composite material can be prepared by combining the polymers with a medium such as and water, and expanding the mixture using a treatment that expands the mixture to produce, for example, insoluble porous foam-like composites.Type: GrantFiled: April 11, 2017Date of Patent: February 28, 2023Assignee: The Penn State Research FoundationInventors: Jeffrey Catchmark, Yuzhi Deng
-
Patent number: 11548946Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-L1 or PD-L2 by administering to the patient a nanoparticle composition and a PD-1 immunotherapy.Type: GrantFiled: August 31, 2017Date of Patent: January 10, 2023Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 11547746Abstract: The present invention relates to a method for preventing and/or treating coronary atherosclerosis and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject, wherein the subject suffers from, is suspected of suffering from coronary atherosclerosis and its related conditions, or has a risk of suffering from coronary atherosclerosis and its related conditions. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating coronary atherosclerosis and its related conditions in a subject.Type: GrantFiled: June 19, 2017Date of Patent: January 10, 2023Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11541011Abstract: A composition in powder form comprising alginic acid or sodium alginate, -pectin and chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder, the process for preparing the powder and its use in the treatment of cutaneous wounds and in the sector of food preservation are described.Type: GrantFiled: November 7, 2018Date of Patent: January 3, 2023Assignee: MATERIAS S.r.l.Inventors: Pasquale Del Gaudio, Rita Patrizia Aquino, Paola Russo, Gianluigi De Falco, Luigi Nicolais
-
Patent number: 11534421Abstract: A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing a matrix composition having a combination of an amount of one or more cannabinoids and a water-insoluble composition. Also, pouches for use as a medicament, for use in alleviation of pain, and for use in mitigation of appetite deficiency are disclosed. Further, a method of alleviation of pain and a method of mitigation of appetite deficiency using the pouch are disclosed.Type: GrantFiled: June 23, 2017Date of Patent: December 27, 2022Inventor: Heidi Ziegler Bruun
-
Patent number: 11491090Abstract: The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 ?m and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to ? of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, wherein the wall material consists of a composition comprising at least one aliphatic-aromatic polyester, and the wall material has a solubility at 25° C. of at least 50 g/l in dichloromethane, a method for the preparation thereof and also the use thereof.Type: GrantFiled: October 4, 2017Date of Patent: November 8, 2022Inventors: Ewelina Burakowska-Meise, Wolfgang Krause, Patrick Leibach, Karl Kolter
-
Patent number: 11466057Abstract: It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells comprising such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.Type: GrantFiled: June 30, 2020Date of Patent: October 11, 2022Assignees: WAGENINGEN UNIVERSITEIT, UNIVERSITÉ CATHOLIQUE DE LOUVAINInventors: Clara Belzer, Willem Meindert De Vos, Patrice Daniel Cani
-
Patent number: 11427637Abstract: Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.Type: GrantFiled: September 5, 2017Date of Patent: August 30, 2022Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 11331270Abstract: The present application relates to a pharmaceutical composition in a form of dry powder for intranasal administration, comprising solid particles of at least one active agent and solid particles of a diluent, said pharmaceutical composition being substantially free of excipients other than the solid diluent, wherein said pharmaceutical composition having at least 90% of the particles of said at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of said at least one active agent with a mean particle size equal to or below 5 microns. The particles of said diluent have a mean particle size of 30-200 microns. The present application also relates to an apparatus and modified spray drying method for preparation of the pharmaceutical composition of the present invention in the dry powder form.Type: GrantFiled: August 19, 2018Date of Patent: May 17, 2022Assignee: Nasus Pharma Ltd.Inventor: Galia Temtsin-Krayz
-
Patent number: 11319367Abstract: Disclosed herein are methods of reducing a symptom of respiratory disease in a pre-weaned milk-fed mammal by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Also included are methods of reducing mixing stress in human and non-human mammals by administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Further included are milk and food compositions including the interleukin-10 peptide or anti-interleukin-10 antibody.Type: GrantFiled: October 9, 2019Date of Patent: May 3, 2022Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Mark Eric Cook, Jordan Marshall Sand, Sheila Mary McGuirk, Jane Ellen Rieman, Sarah Marie Raabis
-
Patent number: 11260359Abstract: The microcapsules and process of making describe a novel core shell microcapsule. The microcapsule incorporates a polysaccharide such as chitosan into the microcapsule wall forming the shell. The microcapsule shell is formed by dissolving chitosan into a material of structure wherein each R is independently selected from hydrogen, C1 to C8 alkyl, or a cyano group; and each y is independently an integer from 1 to 8, and reacting with a multifunctional (meth)acrylate.Type: GrantFiled: January 10, 2020Date of Patent: March 1, 2022Inventors: Presley Genevie Neuman, Linsheng Feng
-
Patent number: 11260025Abstract: An in situ gelling composition comprising nanoparticles comprising soy protein and a bioactive agent, and a sodium alginate film, wherein the nanoparticles are encapsulated in the film. The in situ gelling composition maybe incorporated into a solid dosage form or reconstituted with water for oral administration to a subject in need of sustained release of the bioactive agent.Type: GrantFiled: February 15, 2021Date of Patent: March 1, 2022Assignee: KING ABDULAZIZ UNIVERSITYInventors: Shadab MD, Samaa T. Abdullah, Nabil A. Alhakamy
-
Patent number: 11202766Abstract: Novel hydrocodone bitartrate and guaifenesin pharmaceutical compositions. Methods of making and using the hydrocodone bitartrate and guaifenesin pharmaceutical compositions also are disclosed.Type: GrantFiled: April 23, 2019Date of Patent: December 21, 2021Assignee: ECI Pharmaceuticals, LLCInventors: Solomon Goll, Nirali R. Bhatt
-
Patent number: 11202757Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.Type: GrantFiled: December 1, 2020Date of Patent: December 21, 2021Assignee: Formulex Pharma Innovations Ltd.Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
-
Patent number: 11185122Abstract: Sports boot element comprising all or part of a wall designed to form at least part of a lateral and/or frontal and/or rear and/or lower wall of a sports boot, characterised in that all or part of its wall comprises a material (10) comprising a polymer (11) and a hollow microball (12) filler.Type: GrantFiled: June 11, 2018Date of Patent: November 30, 2021Assignee: ROSSIGNOL LANGE S.R.L.Inventor: Matteo Stefan
-
Patent number: 11185093Abstract: The present invention relates to pulverulent compositions of at least one carotenoid selected from the group consisting of ?-carotene, astaxanthin, canthaxanthin, citranaxanthin, lycopene and lutein, a process for the production of these pulverulent compositions, and the use of the pulverulent compositions.Type: GrantFiled: November 11, 2008Date of Patent: November 30, 2021Inventor: Christian Köpsel
-
Patent number: 11179414Abstract: Disclosed is a method for producing a protease degradation composition by degrading a composition containing a hyaluronic acid and a protein with a protease, in the presence of an ascorbic acid, an ascorbate or a salt thereof. The composition produced according to the method has a high fibroblast proliferation promoting effect and a high collagen production promoting effect.Type: GrantFiled: April 5, 2019Date of Patent: November 23, 2021Assignee: LAIMU CORPORATIONInventor: Sachio Wakayama
-
Patent number: 11154570Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).Type: GrantFiled: April 28, 2020Date of Patent: October 26, 2021Assignee: Particle Dynamics International, LLC.Inventors: Paul Brady, Keith Cromack
-
Patent number: 11116723Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one active agent and solid particles of a diluent. The pharmaceutical composition is substantially free of excipients other than the solid diluent. The pharmaceutical composition has at least 90% of the particles of the at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of the at least one active agent with a mean particle size equal to or below 5 microns. The particles of the diluent have a mean particle size of 30-200 microns. An apparatus and method for preparation of the pharmaceutical composition utilize a spray-drying chamber, a cyclone separator, and a receiving chamber.Type: GrantFiled: November 30, 2020Date of Patent: September 14, 2021Assignee: Formulex Pharma Innovations Ltd.Inventor: Galia Temtsin-Krayz
-
Patent number: 11110151Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.Type: GrantFiled: June 21, 2019Date of Patent: September 7, 2021Assignee: MannKind CorporationInventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
-
Patent number: 11103501Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.Type: GrantFiled: October 3, 2017Date of Patent: August 31, 2021Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
-
Patent number: 11065238Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.Type: GrantFiled: November 3, 2017Date of Patent: July 20, 2021Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), ÉCOLE PRATIQUE DES HAUTES ÉTUDESInventors: Frédéric Darios, Giovanni Stevanin, Fanny Mochel, Julien Branchu, Maxime Boutry
-
Patent number: 11045492Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.Type: GrantFiled: March 12, 2018Date of Patent: June 29, 2021Assignee: onCour Pharma, Inc.Inventor: John Puisis
-
Patent number: 11045464Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.Type: GrantFiled: July 19, 2016Date of Patent: June 29, 2021Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11033602Abstract: Disclosed herein is a pulmonary administration device, comprising a spray nozzle unit and a cartridge containing an aqueous solution comprising from 70 to 400 mg A/m L of a sulfomethylated polymyxin, and use of sulfomethylated polymyxin in a device for pulmonary administration in a patient in need thereof.Type: GrantFiled: October 1, 2015Date of Patent: June 15, 2021Assignee: XELLIA PHARMACEUTICALS APSInventor: Nenad Bencic
-
Patent number: 11013736Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.Type: GrantFiled: July 28, 2017Date of Patent: May 25, 2021Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.Inventors: Lei Liang, Yongkai Chen, Liu Hu, Wei Feng, Chaodong Wang
-
Patent number: 11007279Abstract: A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Colloidally stable non-viral gene vector delivery systems capable of overcoming various biological barriers, are disclosed. The gene vectors are biodegradable, non-toxic and highly tailorable for use in specific applications. The vectors include a mixture of biodegradable copolymers, such as PBAE, and biodegradable polymers conjugated with hydrophilic, neutrally charged polymer, such as PEG. The gene vectors demonstrate broad vector distribution and high transgene delivery in vivo, providing an efficient non-viral gene delivery system for localized therapeutic gene transfer. Methods of using the vectors to overcome biological barriers including mucus gel and extracellular matrix are provided. Methods of formulating the vectors are also provided.Type: GrantFiled: June 4, 2019Date of Patent: May 18, 2021Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Justin Hanes, Jung Soo Suk, Panagiotis Mastorakos
-
Patent number: 10993912Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.Type: GrantFiled: November 22, 2016Date of Patent: May 4, 2021Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 10993911Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.Type: GrantFiled: October 5, 2016Date of Patent: May 4, 2021Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 10912848Abstract: The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.Type: GrantFiled: October 13, 2014Date of Patent: February 9, 2021Assignee: IMGT CO, LTD.Inventors: Hyun Cheol Kim, Hyung Won Moon, Jin Ho Chang
-
Patent number: 10786486Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.Type: GrantFiled: November 16, 2017Date of Patent: September 29, 2020Inventor: Vasilios Voudouris
-
Patent number: 10773231Abstract: This invention relates to a process for colloidosome-type microcapsules elaboration from solid particles microcapsules obtained by ionic gelation. In the process, an (O/W) type emulsion is initially generated stabilized with the solid particles microcapsules, and then the particles are fixed to the interface by adsorption of polyelectrolytes, cross-linking, heat treatment or fatty coating, generating the colloidosome with the water-insoluble phase encapsulated in the core and covered by the shell particles.Type: GrantFiled: June 18, 2016Date of Patent: September 15, 2020Assignees: Nexentia S.A.S., Universidad de AntioquiaInventors: Herley Casanova, César Augusto Pérez Zapata
-
Albumin-CTLA-4 paclitaxel nanopartilce complex compositions and methods of making and using the same
Patent number: 10772833Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.Type: GrantFiled: March 10, 2017Date of Patent: September 15, 2020Assignee: Mayo Foundation for Medical Education and ResearchInventors: Svetomir N. Markovic, Wendy K. Nevala